Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Faivre, Sandrine; Delbaldo, Catherine; Vera, Karina; Robert, Caroline; Lozahic, Stéphanie; Lassau, Nathalie; Bello, Carlo; Deprimo, Samuel; Brega, Nicoletta; Massimini, Giorgio; Armand, Jean-Pierre; Scigalla, Paul; Raymond, Eric

doi:10.1200/jco.2005.02.2194

Public

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Shared by NobleBlocks on Jan 1, 2006 • 12:00 AM UTC

Authors:

Sandrine Faivre

Catherine Delbaldo

Karina Vera

Abstract

Purpose To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies. Patients and Methods Sunitinib was given orally for 4 weeks every 6 weeks....

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!